AAAAAA

   
Results: 1-16 |
Results: 16
Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces
Authors: Ostroff, R Ettinger, A La, H Rihanek, M Zalman, L Meador, J Patick, AK Worland, S Polisky, B
Citation: R. Ostroff et al., Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces, J CLIN VIRO, 21(2), 2001, pp. 105-117
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors
Authors: Webber, SE Marakovits, JT Dragovich, PS Prins, TJ Zhou, R Fuhrman, SA Patick, AK Matthews, DA Lee, CA Srinivasan, B Moran, T Ford, CE Brothers, MA Harr, JEV Meador, JW Ferre, RA Worland, ST
Citation: Se. Webber et al., Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors, BIOORG MED, 11(20), 2001, pp. 2683-2686
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, andantiviral activities (vol 45, pg 1086, 2001)
Authors: Zhang, KYE Wu, E Patick, AK Kerr, B Zorbas, M Lankford, A Kobayashi, T Maeda, Y Shetty, B Webber, S
Citation: Kye. Zhang et al., Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, andantiviral activities (vol 45, pg 1086, 2001), ANTIM AG CH, 45(8), 2001, pp. 2405-2405
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, andantiviral activities
Authors: Zhang, KYE Wu, E Patick, AK Kerr, B Zorbas, M Lankford, A Kobayashi, T Maeda, Y Shetty, B Webber, S
Citation: Kye. Zhang et al., Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, andantiviral activities, ANTIM AG CH, 45(4), 2001, pp. 1086-1093
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors
Authors: Dragovich, PS Zhou, R Webber, SE Prins, TJ Kwok, AK Okano, K Fuhrman, SA Zalman, LS Maldonado, FC Brown, EL Meador, JW Patick, AK Ford, CE Brothers, MA Binford, SL Matthews, DA Ferre, RA Worland, ST
Citation: Ps. Dragovich et al., Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors, BIOORG MED, 10(1), 2000, pp. 45-48
Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor
Authors: Zalman, LS Brothers, MA Dragovich, PS Zhou, R Prins, TJ Worland, ST Patick, AK
Citation: Ls. Zalman et al., Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor, ANTIM AG CH, 44(5), 2000, pp. 1236-1241
Substituted benzamide inhibitors of human rhinovirus 3C protease: Structure-based design, synthesis, and biological evaluation
Authors: Reich, SH Johnson, T Wallace, MB Kephart, SE Fuhrman, SA Worland, ST Matthews, DA Hendrickson, TF Chan, F Meador, J Ferre, RA Brown, EL DeLisle, DM Patick, AK Binford, SL Ford, CE
Citation: Sh. Reich et al., Substituted benzamide inhibitors of human rhinovirus 3C protease: Structure-based design, synthesis, and biological evaluation, J MED CHEM, 43(9), 2000, pp. 1670-1683
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
Authors: Atkinson, B Isaacson, J Knowles, M Mazabel, E Patick, AK
Citation: B. Atkinson et al., Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine, J INFEC DIS, 182(2), 2000, pp. 420-427
Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides
Authors: Dragovich, PS Zhou, R Skalitzky, DJ Fuhrman, SA Patick, AK Ford, CE Meador, JW Worland, ST
Citation: Ps. Dragovich et al., Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides, BIO MED CH, 7(4), 1999, pp. 589-598
Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids
Authors: Dragovich, PS Webber, SE Prins, TJ Zhou, R Marakovits, JT Tikhe, JG Fuhrman, SA Patick, AK Matthews, DA Ford, CE Brown, EL Binford, SL Meador, JW Ferre, RA Worland, ST
Citation: Ps. Dragovich et al., Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids, BIOORG MED, 9(15), 1999, pp. 2189-2194
Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
Authors: Tebas, P Patick, AK Kane, EM Klebert, MK Simpson, JH Erice, A Powderly, WG Henry, K
Citation: P. Tebas et al., Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir, AIDS, 13(2), 1999, pp. F23-F28
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease
Authors: Patick, AK Binford, SL Brothers, MA Jackson, RL Ford, CE Diem, MD Maldonado, F Dragovich, PS Zhou, R Prins, TJ Fuhrman, SA Meador, JW Zalman, LS Matthews, DA Worland, ST
Citation: Ak. Patick et al., In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease, ANTIM AG CH, 43(10), 1999, pp. 2444-2450
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
Authors: Matthews, DA Dragovich, PS Webber, SE Fuhrman, SA Patick, AK Zalman, LS Hendrickson, TF Love, RA Prins, TJ Marakovits, JT Zhou, R Tikhe, J Ford, CE Meador, JW Ferre, RA Brown, EL Binford, SL Brothers, MA DeLisle, DM Worland, ST
Citation: Da. Matthews et al., Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes, P NAS US, 96(20), 1999, pp. 11000-11007
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors
Authors: Shafer, RW Hsu, P Patick, AK Craig, C Brendel, V
Citation: Rw. Shafer et al., Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors, J VIROLOGY, 73(7), 1999, pp. 6197-6202
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure - Activity studiesof ketomethylene-containing peptidomimetics
Authors: Dragovich, PS Prins, TJ Zhou, R Fuhrman, SA Patick, AK Matthews, DA Ford, CE Meador, JW Ferre, RA Worland, ST
Citation: Ps. Dragovich et al., Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure - Activity studiesof ketomethylene-containing peptidomimetics, J MED CHEM, 42(7), 1999, pp. 1203-1212
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P-1 lactam moieties as L-glutamine replacements
Authors: Dragovich, PS Prins, TJ Zhou, R Webber, SE Marakovits, JT Fuhrman, SA Patick, AK Matthews, DA Lee, CA Ford, CE Burke, BJ Rejto, PA Hendrickson, TF Tuntland, T Brown, EL Meador, JW Ferre, RA Harr, JEV Kosa, MB Worland, ST
Citation: Ps. Dragovich et al., Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P-1 lactam moieties as L-glutamine replacements, J MED CHEM, 42(7), 1999, pp. 1213-1224
Risultati: 1-16 |